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Pakshaghata is a Vatavyadhi classified under 
Astamahagada.[1] It is Vata Pradhana Tridoshaja 
Vyadhi, in which among Vata - Prana, Udana, Vyana, 
Apana, in Pitta - Ranjaka, Aalochaka, and Pachaka 
and   in    Kapha  -  Avalambak,   Bodhak,  Tarpak    are  
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associated.[2] Pakshaghata is included in 80 Vata 
Namathmaja Vyadhi.[3] Pakshaghata is caused by 
Dhatukshayajanya and Margavaranjanya. The 
aggravated Vata perfuse through Urdwa, Adhah and 
Tiryak Ghata Dhamanis.[1] In Pakshaghata vitiated 
Vata resides in one half of body and causes 
Vishoshana  of Sira and Snayu leading to loosening of 
joints resulting in symptoms like Cheshta Nivrutti, 
Ruja and Vakstambha.[4] 
Pakshaghata can be correlated to stroke or CVA. In 
1970, the World Health Organization defined stroke 
as ‘rapidly developed clinical signs of focal (or global) 
disturbance of cerebral function, lasting more than 24 
hours or leading to death, with no apparent cause 
other than of vascular origin.[5] The signs and 
symptoms of stroke are sudden numbness or 
weakness in the face, arm, or leg, especially on one 
side of the body , confusion, difficulty speaking, or 
difficulty in understanding speech, trouble seeing in 
A B S T R A C T  
Pakshaghata is one among 80 Vata Namathmaja Vyadhi. In Pakshaghata vitiated Vata resides  in  one 
half of body and causes Vishoshana  of Sira  and Snayu   leading  to  loosening  of  joints  results into 
manifestation of   symptoms    like Cheshta    Nivrutti, Ruja and Vakstambha. Pakshaghata can be 
correlated to stroke or CVA. The study aims to evaluate the combined effectiveness of Maharasnadi 
Kashaya with Shunti Churna as Anupana in management of Pakshaghata (CVA due to infarct). The 
open label prospective clinical study was conducted among the 32 patients of Pakshaghata by 
convenient sampling method at a tertiary Hospital Sri Dharmasthala Manjunatheshwara College of 
Ayurveda & Hospital, Hassan, Karnataka from December 2018 to December 2019. The effectiveness of 
the drug showed improvement in primary outcome measures such as Cheshta Nivrutti, Vakstambha 
and Ruk in subjects of Pakshaghata with p value < 0.05. In this study, maximum improvement was 
found in “Ruk” followed by “Cheshta Nivrutti” and then “Vak Stambha”. Hence this drug is more 
effective in “Saruja Pakshaghata” hence; it showed improvement in the NIH stroke scale parameters 
with p value < 0.05. The combined effectiveness of Maharasnadi Kashaya with Shunti Churna as 
Anupana in management of Pakshaghata (CVA due to Infarct) is proved. 
Key words: Pakshaghata, Cerebro Vascular Accident (CVA due to Infract), Maharasnadi Kashaya, 
Shunti Churna. 
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one or both eyes, trouble in walking, dizziness, loss of 
balance, or lack of coordination, severe headache 
with no known cause. According to CDC stroke can be 
classified into 3, they are ischemic stroke, cerebral 
stroke and transient ischemic attack.[9] 
World stroke organization report of 2018 gives the 
data of annual risk of stroke inclusive of all risk 
combined accounts for 88.8%. Metabolic blood 
systolic high pressure, high body mass index, high 
fasting plasma glucose, high total cholesterol and low 
glomerular filtration rate accounts for 72.1%. 
Behavioral factors such as smoking, poor diet and low 
physical activity accounts for 66.3%. Of all 
hypertension solely contributes 57.3% of risk of 
stroke.[6] 
Annually five and half million people die of stroke. 
53% and 47% die each year of stroke in male and 
female respectively. Less than 44 years of age 4% all 
death and fewer than 70 years of age 39% of all 
deaths are from stroke.[7] According Indian statistics 
7,00,000 populations is affected by stroke every year. 
10% recover completely, 25% live with minor 
impairment, 40% live with moderate to severe 
impairment, 10% require care in hospital and 15% die 
shortly after the stroke.[1] 
Acharya Charaka describes the treatment of 
Pakshaghata is Swedana, Snehana and Virechana.[2] In 
modern science treatment for stroke is thrombolysis, 
antiplatelet agents, anticoagulation, neuroprotector 
and rehabilitation. 
According to Sharangdhara Samhita, Maharasnadi 
Kashaya with Shunti Churna Anupana is used to treat 
Pakshaghata.[8] Maharasnadi Kashaya is a formulation 
comprising of 26 drugs which is contribution of 
Sharangdhar Samhita. As per the claim of classical 
textbook it is indicated in treatment of Pakshaghata 
along with Shunti Churna Anupana. This contains Tikta 
Rasa, Katu Vipaka, Ushna Veerya and Guru, Snigdha 
Guna, Vatakapha Shamaka, Rasayan, Deepana, 
Hrudya, Medhya Karma. Therefore this study intends 
to evaluate the combined effectiveness of 
Maharasnadi Kashaya with Shunti Churna as Anupana 
in management Pakshaghata (CVA due to infarct).  
MATERIALS AND METHODS 
Study setting  
Out Patient Department of Sri Dharmasthala 
Manjunatheshwara Ayurveda College & Hospital, 
Hassan, Karnataka, India.   
Study population 
Patients with Pakshaghata Lakshana 
Study period  
December 2018 - December 2019  
Inclusion criteria  
Chesta Nivritti, Vaaksthambha and Ruja. 
Subjects aged between 30yrs - 75yrs. 
Pakshaghata associated with disease like controlled 
Diabetes Mellitus, Hypertension, Hyperlipidemia (Any 
of these or all of these). 
Those who are ready to sign the informed consent 
form. 
Exclusion criteria  
▪ Known case of HBsAg, HIV, Carcinoma, Renal 
disorders, COPD. 
▪ History of evidence of Intra Cranial Infection - 
Encephalitis, Meningitis, Cerebral Tumor, Cerebral 
Abscess. 
▪ Congenital Defects - Diffused Sclerosis, Cerebral 
Agenesis.  
Sampling technique  
Convenient sample 
Sample size - 32 
Statistical method/ analysis 
Data is entered using SPSS 20 and data is analysed. 
For significance of change in Nominal data McNemar 
test was performed  
For significance of change in Ordinal data Wilcoxon 
signed rank test was performed 
Rohan Mohandas et al. Clinical study in the management of Pakshaghata (CVA due to infarct) 
ISSN: 2456-3110                                                   ORIGINAL ARTICLE Sept-Oct 2020 
 
Journal of Ayurveda and Integrated Medical Sciences | Sept - Oct  2020 | Vol. 5 | Issue 5 61 
 









IEC No- SDM/IEC/62/2018-19 
CTRI No- CTRI/2019/04/018440 
Intervention  
An intervention was planned to administer 
Maharasnadi Kashaya 50ml with Shunti Churna 
Anupana 1½ grams twice daily after food for 7 days 
which was prepared in teaching Pharmacy of SDM 
College of Ayurveda, Hassan.  
Grouping  
62 patients who attended OPD were screened, among 
them 32 patients were included in the study and 
administered the drug. 
Source and authentication of the drug   
Maharasnadi Kashaya raw drug was purchased from 
CKKM pharmacy, Kerala and Shunti Churna was 
purchased from Sri Dharmasthala Manjunatheshwara 
Ayurveda pharmacy, Hassan. 
RESULTS 
32 patients were screened and enrolled in the clinical 
trial completed their course of treatment for 7 days 
was assessed with before and after treatment. The 
socio demographic data of the patient’s shows that 
average age of the patients enrolled in the study was 
from 51 to 60 and among the gender male were 26 in 
number see table number 1 patient characteristic.  
Table 1: Patient characteristic 
Age Frequency (N=32) Percentage  
Less than 40  3 9.4% 
41-50 7 21.9% 
51-60 13 40.6% 
61- 70 6 18.8% 
Above 70  3 9.4% 
Gender  
Male  26 81.3% 
Female  6 18.8% 
The effectiveness of the drug imperatively evaluated 
with improvement in Cheshta Nivrutti, 
Vaaksthambha, Ruja and NIH stroke scale, which 
showed improvement among the patients.  
The primary outcome measure was assessed by 
Chesta Nivritti, Vaaksthambha and Ruja. Cheshta 
Nivritti was improved in 24 patients Vakstambha was 
improved in 11 patients and Ruk was improved in 28 
patients. Statistically Wilcoxon signed rank test 
showed significant p value see table number 2primary 
outcome measures.  
























































Inclusive subjects were enrolled with consent for 
drug administration and assessed for drug efficacy 
Screening was done using all the points of history 
taking and physical examination mentioned in 
Ayurveda texts as well as contemporary texts 
Patient attending OPD of SDM, Hassan were 
screened 
Ethical clearance was taken from IEC and register 
in CTRI 
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The secondary outcome measures was assessed by 
Wilcoxon signed rank test for muscle power of both 
upper and lower limbs statistically test showed 
significant value and there was improvement after the 
treatment. NIH stroke scale showed significant 
improvement in motor arm drift, motor leg drift and 
dysarthria see table number 3 NIH stroke scale. 
































































































The combination of 26 drugs in Maharasnadi Kashaya 
contains Tikta Rasa, Katu Vipaka, Ushna Veerya and 
Guru, Snigdha Guna, Vatakapha Shamaka, Rasayana, 
Deepana, Hrudya and Medhya Karma. Acharya 
Vagbhata in Ashtanga Sangraha has opined that any 
treatment should be given for 7 days, if there is no 
improvement in this duration then other Chikitsa 
should be opted once the power of the first Chikitsa 
subsides.[10] If there is mild improvement in the 
treatment to get maximum benefit treatment should 
be continued.[10] Hence Maharasnadi Kashaya with 
Shunti Churna is administered for 7 days. Rasna has 
Usna, Tikshna Guna, Guru, Vatakaphashamak and 
Pachak it opens all micro channels and reaches 
cellular level to show its neuro generative anabolic 
and adaptive effect.[11] Shunti, Nagara, Pippali, 
Haritaki,Chavya, Musta, Prativisha, Dhanyaka and 
Sahachara acts as Deepana and Pachana.  Bala, 
Eranda, Haritaki, Punarnava, Guduchi, Vriddadharu, 
Ashwagandha, Shatavari and Pippali act as Oja 
Vardhaka, Rasayana, Balya, Vrushya, Brmhana, Smirti 
Prada, Medhya, Nadi Balya and Pushtikara. 
Cheshta Nivritti 
Statistically significant improvement was noticed in 
Cheshta Nivritti after treatment. Wilcoxon signed rank 
test (P value = 0.000) showed improvements in mean 
after treatment. Cheshta Nivritti is manifested due to 
the Vyana Vata Prakopa. The Sthana of Vyana Vata is 
Hrudaya. The combination of drugs such as Bala, 
Vasa, Nagara, haritaki, Guduchi, Dhanyaka, Gokshura 
and Kantakari acts as Hrudya and Vata Pradhana 
Tridoshahara. Hence these drugs act on Vyana Vata 
to reduce Cheshta Nivritti.[12] Another cause of 
Cheshtanivritti is Shoshana of Sira and Snayu, Rasna’s 
Guru Snigdha Lakshana may help to reduce the 
same.[13]  
Rasna contains chemical components such as 
pluchine, flavonoids, quercetin and isorhamnetin. 
Pluchine acts as CNS stimulant, neuro protective 
action, neuro modulatory and pyramidal neurons.[14] 
Flavonoids have both antioxidant and antithrombotic 
property.[15] Quercetin, attenuate severe neurological 
deficits and reduces infarct volume. Isorhamnetin 
improves blood brain barrier function.[16] 
Cheshta Nivritti is due to Shoshana of Sira and Snayu 
which are Upadhatus of Rakta Doshas. Rakta 
Prasadaka and Deepana Pachana drugs such as Vasa, 
Shunti, Gokshura, Guduchi, Kantakari, Vacha, Pippali, 
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Haritaki, Nagara, Punarnava, Shatavari, Kritamala 
drugs nourishes Rakta and its Upadhatus. 
Vak Stambha 
Statistically significant improvement was noticed in 
Vak Stambha after treatment. Wilcoxon signed rank 
test (P value = 0.001) showed improvements in mean 
after treatment. Kaphavrutaudana causes Vak 
Stambha. Rasna, Devadaru, Shati, Nagara, Vacha, 
Chavya, Vriddadharu, Shatapushpa, Ashwagandha, 
Pippali, Sahachara, Kantakari and Bruhati might have 
acted as Margavaranahara and Kapha Nisaraka 
leading to the normal Gati of Udana and Pranavata. 
Vacha and Kantakari which is Swara Krut and Kanthya 
(euegnol and asarone) improved the speech.  
Ruk 
Statistically significant improvement was noticed in 
Ruk after treatment. Wilcoxon signed rank test (P 
value = 0.000) showed improvements in mean after 
treatment. Ruk is caused by Vata Dosha which is 
counteracted by the Vata Shamaka Dravyas like 
Rasna, Eranda, Gokshura, Haritaki, Ashwagandha, 
and Shunti. Rasna, Eranda, Shati, Shatapushpa, 
Kritamala, Sahachara, Bruhati are Shoola Prashamana 
Dravyas (lupenol, strearic acid, quercetin etc.).[17] 
CONCLUSION 
The Combined effect of Maharasnadi Kashaya with 
Shunti Churna Anupana showed improvement in 
primary outcome measures such as Cheshta Nivritti, 
Vakstambha and Ruk in subjects of Pakshaghata with 
p value < 0.05. In this study, maximum improvement 
was found in “Ruk” followed by “Cheshta Nivritti” and 
then “Vak Stambha”. Hence this drug is more 
effective in “Saruja Pakshaghata”. It showed 
improvement in the NIH stroke scale parameters with 
p value < 0.05. Adverse drug reactions were not 
reported during the study. The combined 
effectiveness of Maharasnadi Kashaya with Shunti 
Churna Anupana in management of Pakshaghata 
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